Compare WVE & THQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | THQ |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.8M | 784.0M |
| IPO Year | 2015 | N/A |
| Metric | WVE | THQ |
|---|---|---|
| Price | $3.88 | $17.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 18 | 0 |
| Target Price | ★ $18.53 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 101.4K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | $20.53 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $3.56 | $16.28 |
| 52 Week High | $21.73 | $20.39 |
| Indicator | WVE | THQ |
|---|---|---|
| Relative Strength Index (RSI) | 36.57 | 34.78 |
| Support Level | N/A | $18.02 |
| Resistance Level | $6.33 | $18.50 |
| Average True Range (ATR) | 0.21 | 0.26 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 38.99 | 21.12 |
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies. The fund invests in equity and debt securities of public and private healthcare companies believed by the Fund's Adviser to have potential for above-average growth, and may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, provided these securities comprise 10% or less of Managed Assets.